Latest in Cardiology from ACC.org

• DapaTAVI Substudy: Does Dapagliflozin Improve Health Status Post TAVI?
  Although dapagliflozin may reduce death or worsening heart failure (HF) in patients with aortic stenosis (AS) undergoing TAVI, it showed limited improvement in patients' health status post TAVI, according to a prespecified subanalysis of the DapaTAVI trial published Oct. 6 in JACC.
• Eagle’s Eye View: A Look at ACC’s Scientific Statement on Inflammation and CVD
  In this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD).
• JACC State-of-the-Art Review: Benefits of Anti-Inflammatories Post AMI
  A JACC State-of-the-Art Review provides a comprehensive and current overview of inflammatory mechanisms post-acute myocardial infarction (AMI) and evaluates the current evidence for anti-inflammatory therapies for secondary cardiovascular prevention.
• Exposure to Tobacco Retail Increases Smoking, Craving in People Who Smoke
  Exposure to tobacco retail was associated with increases in smoking and smoking craving in people who smoke cigarettes daily, according to research published Sept. 29 in JAMA Network Open.
• AI-Derived Body Composition Measurements Predict Cardiometabolic Risk
  Body composition (BC) measurements derived using artificial intelligence (AI) are strongly linked to cardiometabolic risk, but after adjusting for BMI and waist circumference (WC), only visceral adipose tissue (VAT) proportion and skeletal muscle fat fraction (SMFF)...